IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression

Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1565-70. doi: 10.1152/ajpheart.00146.2010. Epub 2010 Mar 12.

Abstract

Congestive heart failure is associated with activation of the renin-angiotensin system and skeletal muscle wasting. Angiotensin II (ANG II) has been shown to increase muscle proteolysis and decrease circulating and skeletal muscle IGF-1. We have shown previously that skeletal muscle-specific overexpression of IGF-1 prevents proteolysis and apoptosis induced by ANG II. These findings indicated that downregulation of IGF-1 signaling in skeletal muscle played an important role in the wasting effect of ANG II. However, the signaling pathways and mechanisms whereby IGF-1 prevents ANG II-induced skeletal muscle atrophy are unknown. Here we show ANG II-induced transcriptional regulation of two ubiquitin ligases atrogin-1 and muscle ring finger-1 (MuRF-1) that precedes the reduction of skeletal muscle IGF-1 expression, suggesting that activation of atrogin-1 and MuRF-1 is an initial mechanism leading to skeletal muscle atrophy in response to ANG II. IGF-1 overexpression in skeletal muscle prevented ANG II-induced skeletal muscle wasting and the expression of atrogin-1, but not MuRF-1. Dominant-negative Akt and constitutively active Foxo-1 blocked the ability of IGF-1 to prevent ANG II-mediated upregulation of atrogin-1 and skeletal muscle wasting. Our findings demonstrate that the ability of IGF-1 to prevent ANG II-induced skeletal muscle wasting is mediated via an Akt- and Foxo-1-dependent signaling pathway that results in inhibition of atrogin-1 but not MuRF-1 expression. These data suggest strongly that atrogin-1 plays a critical role in mechanisms of ANG II-induced wasting in vivo.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / antagonists & inhibitors*
  • Angiotensin II / toxicity*
  • Animals
  • Atrophy
  • Electroporation
  • Forkhead Transcription Factors / antagonists & inhibitors*
  • Gene Expression Regulation / drug effects
  • Humans
  • Immunoblotting
  • Insulin-Like Growth Factor I / pharmacology*
  • Luciferases / biosynthesis
  • Luciferases / genetics
  • Mice
  • Mice, Inbred C57BL
  • Muscle Proteins / biosynthesis*
  • Muscle Proteins / genetics
  • Muscle, Skeletal / drug effects*
  • Muscle, Skeletal / pathology*
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-akt / physiology
  • Reverse Transcriptase Polymerase Chain Reaction
  • SKP Cullin F-Box Protein Ligases / biosynthesis*
  • Signal Transduction / drug effects
  • Tripartite Motif Proteins
  • Ubiquitin-Protein Ligases / biosynthesis
  • Ubiquitin-Protein Ligases / genetics
  • Up-Regulation / drug effects

Substances

  • Forkhead Transcription Factors
  • Muscle Proteins
  • Tripartite Motif Proteins
  • Angiotensin II
  • Insulin-Like Growth Factor I
  • Luciferases
  • Fbxo32 protein, mouse
  • SKP Cullin F-Box Protein Ligases
  • Trim63 protein, mouse
  • Ubiquitin-Protein Ligases
  • Proto-Oncogene Proteins c-akt